Cargando…

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience

INTRODUCTION: Anti-vascular endothelial growth factor (VEGF) therapy is the first-line treatment for diabetic macular edema (DME). We investigated the effect of initial glycosylated hemoglobin (HbA1c) level and glomerular filtration rate (GFR) on treatment outcomes in patients with DME receiving ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Debourdeau, Eloi, Medard, Robin, Chamard, Chloe, Nguyen, Vuong, Gabrielle, Pierre Henry, Creuzot-Garcher, Catherine, Allieu, Sandrine, Gillies, Mark C., Barthelmes, Daniel, Daien, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441844/ https://www.ncbi.nlm.nih.gov/pubmed/37505396 http://dx.doi.org/10.1007/s40123-023-00758-1

Ejemplares similares

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in Diabetic Macular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital
por: Ku, Wei-Ning, et al.
Publicado: (2022)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice
por: Plaza-Ramos, Pablo, et al.
Publicado: (2019)

Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch
por: Kucukevcilioglu, Murat, et al.
Publicado: (2023)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
por: Nawar, Amin E., et al.
Publicado: (2022)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi, Nasser G, et al.
Publicado: (2021)

Association Between Vision and Brain Cortical Thickness in a Community-Dwelling Elderly Cohort
por: Chamard, Chloé, et al.
Publicado: (2022)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions
por: Shen, Weiyong, et al.
Publicado: (2017)

New Keratoconus Risk Factors: A Cross-Sectional Case—Control Study
por: Debourdeau, Eloi, et al.
Publicado: (2022)

Direct association of visit-to-visit HbA1c variation with annual decline in estimated glomerular filtration rate in patients with type 2 diabetes
por: Takenouchi, Akiko, et al.
Publicado: (2015)

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema
por: Sarda, Valérie, et al.
Publicado: (2020)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2020)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study
por: Akbas, Yusuf Berk, et al.
Publicado: (2023)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Glomerular filtration rate is altered in children with sickle cell disease: a comparison between Hb SS and Hb SC
por: de Paula, Rafael Pereira, et al.
Publicado: (2013)

Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion
por: Nghiem-Buffet, Sylvia, et al.
Publicado: (2018)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Bayat, Alper Halil, et al.
Publicado: (2019)

Real-life outcomes of intravitreal ranibizumab, aflibercept, and dexamethasone implant administrations in patients with treatment-naïve diabetic macular edema
por: Korkmaz, Anil, et al.
Publicado: (2021)

Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective
por: Adedokun, Lola, et al.
Publicado: (2016)

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
por: Régnier, Stephane A, et al.
Publicado: (2015)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
por: Kaya, Mahmut, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life
por: Schmid, Martin K., et al.
Publicado: (2015)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hom3lbir4p31q0f8jh2bvvf7pi